Retatrutide: The Triple Agonist Posting the Biggest Numbers Yet
Retatrutide, an investigational GLP-1/GIP/glucagon triple agonist: how it works, the Phase 2 weight-loss figures, and what the safety data shows so far.
Retatrutide is an investigational peptide that has drawn significant attention for its results in obesity and metabolic trials. Unlike single-target drugs, it acts on three receptors at once — which is why it's often described as a "triple agonist." This guide summarizes what the published research shows, in plain language.
Retatrutide is not an approved medication. It remains investigational and is being studied in clinical trials. Nothing here is medical advice.
What is retatrutide?
Retatrutide (development code LY3437943) is a peptide developed as a treatment for obesity and type 2 diabetes. It belongs to the same broad family as semaglutide and tirzepatide, but it targets an additional receptor.
It activates:
- GLP-1 receptors — involved in appetite, satiety and insulin response
- GIP receptors — involved in insulin secretion and fat metabolism
- Glucagon receptors — involved in energy expenditure
The glucagon receptor activity is the key difference from tirzepatide, and researchers believe it may contribute to higher energy expenditure. For the full breakdown, see how retatrutide works.
What the trials report
In a Phase 2 trial published in The New England Journal of Medicine, participants taking the highest dose of retatrutide saw substantial average body-weight reductions over 48 weeks — figures that were notably larger than those reported for earlier-generation drugs at comparable points.
Reported findings across studies include:
- Significant average weight reduction at higher doses
- Improvements in markers of blood sugar control
- Reductions in liver fat in relevant sub-studies
Phase 3 trials are ongoing, and Phase 3 data is what regulators use to make approval decisions. Until that completes, all conclusions are preliminary. For the full set of numbers with sources, see retatrutide results.
Side effects reported in studies
The side-effect profile reported in trials is broadly similar to other incretin-based drugs, and is mostly gastrointestinal:
| Reported effect | Notes |
|---|---|
| Nausea | Most common, typically dose-related |
| Diarrhea | Common, often eases over time |
| Vomiting | Less common, more likely at higher doses |
| Constipation | Reported in some participants |
Trial protocols typically use gradual dose escalation to reduce these effects. For more detail on how trials structure this, see our guide on retatrutide dosing in clinical trials, and for the full safety picture, see retatrutide side effects.
How it compares
Retatrutide is frequently compared with tirzepatide and semaglutide. The short version: it targets one more receptor than tirzepatide, and early data suggests strong efficacy — but it is earlier in development and not yet approved, while the others already are.
For the direct decision-style breakdown, read tirzepatide vs retatrutide.
The bottom line
Retatrutide is one of the most closely watched peptides in metabolic medicine, and early-phase data has been striking. But "investigational" is the operative word: it has not completed Phase 3, is not approved, and should not be obtained or used outside a clinical trial or licensed medical setting.
If you're researching retatrutide, treat current information as provisional and talk to a qualified healthcare professional before making any decisions.